OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Lars Holger Ehlers, Mark Lamotte, Sofia Monteiro, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 5, pp. 1523-1534
Open Access | Times Cited: 16
Lars Holger Ehlers, Mark Lamotte, Sofia Monteiro, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 5, pp. 1523-1534
Open Access | Times Cited: 16
Showing 16 citing articles:
First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Jin Choi, Aaron N. Winn, M. Reza Skandari, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 10, pp. 1392-1400
Open Access | Times Cited: 52
Jin Choi, Aaron N. Winn, M. Reza Skandari, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 10, pp. 1392-1400
Open Access | Times Cited: 52
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Cost-effectiveness analysis and medication use for gangrene treatment in type 2 diabetes patients: A systematic literature review
Entris Sutrisno, Jajang Japar Sodik, Taufik Muhammad Fakih
Pharmacia (2025) Vol. 72, pp. 1-22
Open Access
Entris Sutrisno, Jajang Japar Sodik, Taufik Muhammad Fakih
Pharmacia (2025) Vol. 72, pp. 1-22
Open Access
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
John Wilding, Marc Evans, Kevin Fernando, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 5, pp. 847-872
Open Access | Times Cited: 17
John Wilding, Marc Evans, Kevin Fernando, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 5, pp. 847-872
Open Access | Times Cited: 17
Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review
Mari Pesonen, Virpi Jylhä, Eila Kankaanpää
JBI Evidence Synthesis (2024) Vol. 22, Iss. 11, pp. 2194-2266
Open Access | Times Cited: 2
Mari Pesonen, Virpi Jylhä, Eila Kankaanpää
JBI Evidence Synthesis (2024) Vol. 22, Iss. 11, pp. 2194-2266
Open Access | Times Cited: 2
Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
Spyros Kolovos, L Bellanca, Harinala Groyer, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 6, pp. 3385-3397
Open Access | Times Cited: 6
Spyros Kolovos, L Bellanca, Harinala Groyer, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 6, pp. 3385-3397
Open Access | Times Cited: 6
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 3, pp. 489-503
Open Access | Times Cited: 9
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 3, pp. 489-503
Open Access | Times Cited: 9
Odette S. Reifsnider, Pratik Pimple, Sarah Brand, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 4, pp. 652-661
Open Access | Times Cited: 11
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations
Alper Sönmez, Hani Sabbour, Akram Echtay, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 5, pp. 315-333
Open Access | Times Cited: 7
Alper Sönmez, Hani Sabbour, Akram Echtay, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 5, pp. 315-333
Open Access | Times Cited: 7
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
Hui Shao, Abdul Jabbar Omar Alsaleh, Terry Dex, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 9, pp. 1659-1670
Open Access | Times Cited: 7
Hui Shao, Abdul Jabbar Omar Alsaleh, Terry Dex, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 9, pp. 1659-1670
Open Access | Times Cited: 7
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 9, pp. 2499-2515
Open Access | Times Cited: 8
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 9, pp. 2499-2515
Open Access | Times Cited: 8
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
Rory J. McCrimmon, Karen Palmer, Abdul Jabbar Omar Alsaleh, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 6, pp. 1203-1214
Open Access | Times Cited: 5
Rory J. McCrimmon, Karen Palmer, Abdul Jabbar Omar Alsaleh, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 6, pp. 1203-1214
Open Access | Times Cited: 5
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes
Marc Evans, Sasha Berry, Avideh Nazeri, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 639-648
Closed Access | Times Cited: 5
Marc Evans, Sasha Berry, Avideh Nazeri, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 639-648
Closed Access | Times Cited: 5
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
Ryan Pulleyblank, Nikolaj Birk Larsen
PharmacoEconomics - Open (2023) Vol. 7, Iss. 4, pp. 579-591
Open Access | Times Cited: 1
Ryan Pulleyblank, Nikolaj Birk Larsen
PharmacoEconomics - Open (2023) Vol. 7, Iss. 4, pp. 579-591
Open Access | Times Cited: 1
VK2 Promotes Osteogenic Differentiation of BMSCs against High Glucose Exposure via Modulation of Intracellular Oxidative Stress
Wenlai Fang, Yi-yun Lv, Shu-Qing Jin, et al.
Current Pharmaceutical Design (2023) Vol. 29, Iss. 9, pp. 713-722
Closed Access
Wenlai Fang, Yi-yun Lv, Shu-Qing Jin, et al.
Current Pharmaceutical Design (2023) Vol. 29, Iss. 9, pp. 713-722
Closed Access
